Pantothenate kinase-associated neurodegeneration (Hallerworden–Spatze disease): clinical aspects, diagnosis, treatment (literature review and own data)

Authors

  • Yu. H. Antypkin State Institution “Institute of Pediatrics, Obstetrics and Gynecology named after acad. O. M. Lukyanova of the NAMS of Ukraine”, Kyiv, Ukraine https://orcid.org/0000-0002-8018-4393
  • L. H. Kyrylova State Institution “Institute of Pediatrics, Obstetrics and Gynecology named after acad. O. M. Lukyanova of the NAMS of Ukraine”, Kyiv, Ukraine https://orcid.org/0000-0002-9879-1132
  • O. O. Miroshnykov State Institution “Institute of Pediatrics, Obstetrics and Gynecology named after acad. O. M. Lukyanova of the NAMS of Ukraine”, Kyiv, Ukraine https://orcid.org/0000-0002-7614-6335
  • O. O. Yuzva State Institution “Institute of Pediatrics, Obstetrics and Gynecology named after acad. O. M. Lukyanova of the NAMS of Ukraine”, Kyiv, Ukraine https://orcid.org/0000-0002-0918-4788
  • L. Yu. Silaieva State Institution “Institute of Pediatrics, Obstetrics and Gynecology named after acad. O. M. Lukyanova of the NAMS of Ukraine”, Kyiv, Ukraine
  • O. V. Berehela State Institution “Institute of Pediatrics, Obstetrics and Gynecology named after acad. O. M. Lukyanova of the NAMS of Ukraine”, Kyiv, Ukraine
  • L. A. Myroniak SI “Institute of Nuclear Medicine and Diagnostic Radiology of the NAMS of Ukraine”, Kyiv, Ukraine

DOI:

https://doi.org/10.14739/2310-1210.2021.5.222677

Keywords:

pantothenate kinase-associated neurodegeneration, brain, Hallervorden–Spatz disease, neurodegeneration with brain iron accumulation

Abstract

Aim. To analyze current data of scientific literature on the etiology, pathogenesis, approaches to the diagnosis and treatment of rare orphan disease – pantothenate kinase-associated neurodegeneration and to describe the clinical case of this disease.

Pantothenate kinase-associated neurodegeneration (PKAN) is a rare inherited autosomal recessive disorder caused by mutations in the PANK2 gene, which is located at the chromosomal locus: 20p13-p12.3.

The article presents a literature review and a case report of the diagnosis and treatment of 8-year-old girl with pantothenate kinase-associated neurodegeneration who suffered from progressive motor impairment.

Among the dominant clinical manifestations is a growing extrapyramidal motor disorder, the so-called “dystonic storm”, which can range from severe sensorimotor motor deficits in infants and young children to mild parkinsonism in adults. MRI signs in the form of specific changes in the T2-weighted mode, which detects typical areas of hyperintensive signal in globus pallidus, surrounded by a border of hypointensive signal (“tiger’s eye”) are particular important. Neuroimaging data most likely make possible to suspect a correct diagnosis, reducing the time and cost of additional examinations.

There is no pathogenetic treatment of this disease now. The main directions of currently available symptomatic drug therapy are described. Clinical trials of detoxifying drugs that reduce iron levels in the body (chelation) and surgical treatments are currently underway.

Conclusions. The presented clinical observation once again confirms the complexity of the diagnostic search for orphan diseases of the nervous system. A key place in the diagnosis of pantothenate kinase-associated neurodegeneration belongs to the neuroimaging methods and molecular genetic testing data.

Author Biographies

Yu. H. Antypkin, State Institution “Institute of Pediatrics, Obstetrics and Gynecology named after acad. O. M. Lukyanova of the NAMS of Ukraine”, Kyiv

MD, PhD, DSc, Prof., Academician of the National Academy of Medical Sciences of Ukraine, Director of the State Institution “Institute of Pediatrics, Obstetrics and Gynecology named after acad. O. M. Lukyanova of the NAMS of Ukraine”, Kyiv.

L. H. Kyrylova, State Institution “Institute of Pediatrics, Obstetrics and Gynecology named after acad. O. M. Lukyanova of the NAMS of Ukraine”, Kyiv

MD, PhD, DSc, Scientific Director of the Department of Psychoneurology for Children with Perinatal Pathology and Orphan Diseases

O. O. Miroshnykov, State Institution “Institute of Pediatrics, Obstetrics and Gynecology named after acad. O. M. Lukyanova of the NAMS of Ukraine”, Kyiv

MD, PhD, Senior Researcher of the Department of Psychoneurology for Children with Perinatal Pathology and Orphan Diseases

O. O. Yuzva, State Institution “Institute of Pediatrics, Obstetrics and Gynecology named after acad. O. M. Lukyanova of the NAMS of Ukraine”, Kyiv

Junior Researcher of the Department of Psychoneurology for Children with Perinatal Pathology and Orphan Diseases

L. Yu. Silaieva, State Institution “Institute of Pediatrics, Obstetrics and Gynecology named after acad. O. M. Lukyanova of the NAMS of Ukraine”, Kyiv

Head of the Department of Psychoneurology for Children with Perinatal Pathology and Orphan Diseases

O. V. Berehela, State Institution “Institute of Pediatrics, Obstetrics and Gynecology named after acad. O. M. Lukyanova of the NAMS of Ukraine”, Kyiv

MD, Pediatric Neurologist of the Department of Psychoneurology for Children with Perinatal Pathology and Orphan Diseases

L. A. Myroniak, SI “Institute of Nuclear Medicine and Diagnostic Radiology of the NAMS of Ukraine”, Kyiv

MD, PhD, Head of MRI Reference-centrum

References

  1. Mastrangelo, M. (2019). Clinical approach to neurodegenerative disorders in childhood: an updated overview. Acta Neurologica Belgica, 119(4), 511-521. https://doi.org/10.1007/s13760-019-01160-0
  2. Hogarth, P. (2015). Neurodegeneration with Brain Iron Accumulation: Diagnosis and Management. Journal of Movement Disorders, 8(1), 1-13. https://doi.org/10.14802/jmd.14034
  3. Lehéricy, S., Roze, E., Goizet, C., & Mochel, F. (2020). MRI of neurodegeneration with brain iron accumulation. Current Opinion in Neurology, 33(4), 462-473. https://doi.org/10.1097/WCO.0000000000000844
  4. Bokhari, M., Zulfiqar, H., & Bokhari, S. R. (2021). Hallervorden Spatz Disease. StatPearls. https://www.statpearls.com/ArticleLibrary/viewarticle/22494
  5. Lee, J. H., Park, J., Ryu, H. S., Park, H., Kim, Y. E., Hong, J. Y., Nam, S. O., Sung, Y. H., Lee, S. H., Lee, J. Y., Lee, M. J., Kim, T. H., Lyoo, C. H., Chung, S. J., Koh, S. B., Lee, P. H., Cho, J. W., Park, M. Y., Kim, Y. J., Sohn, Y. H., … Lee, M. S. (2016). Clinical Heterogeneity of Atypical Pantothenate Kinase-Associated Neurodegeneration in Koreans. Journal of Movement Disorders, 9(1), 20-27. https://doi.org/10.14802/jmd.15058
  6. Hogarth, P., Kurian, M. A., Gregory, A., Csányi, B., Zagustin, T., Kmiec, T., Wood, P., Klucken, A., Scalise, N., Sofia, F., Klopstock, T., Zorzi, G., Nardocci, N., & Hayflick, S. J. (2017). Consensus clinical management guideline for pantothenate kinase-associated neurodegeneration (PKAN). Molecular Genetics and Metabolism, 120(3), 278-287. https://doi.org/10.1016/j.ymgme.2016.11.004
  7. Razmeh, S., Habibi, A. H., Orooji, M., Alizadeh, E., Moradiankokhdan, K., & Razmeh, B. (2018). Pantothenate kinase-associated neurodegeneration: Clinical aspects, diagnosis and treatments. Neurology International, 10(1), Article 7516. https://doi.org/10.4081/ni.2018.7516
  8. Chang, X., Zhang, J., Jiang, Y., Wang, J., & Wu, Y. (2020). Natural history and genotype-phenotype correlation of pantothenate kinase-associated neurodegeneration. CNS Neuroscience & Therapeutics, 26(7), 754-761. https://doi.org/10.1111/cns.13294
  9. Akcakaya, N. H., Iseri, S. U., Bilir, B., Battaloglu, E., Tekturk, P., Gultekin, M., Akar, G., Yigiter, R., Hanagasi, H., Alp, R., Cagirici, S., Eraksoy, M., Ozbek, U., & Yapici, Z. (2017). Clinical and genetic features of PKAN patients in a tertiary centre in Turkey. Clinical Neurology and Neurosurgery, 154, 34-42. https://doi.org/10.1016/j.clineuro.2017.01.011
  10. Zeng, J., Xing, W., Liao, W., & Wang, X. (2019). Magnetic resonance imaging, susceptibility weighted imaging and quantitative susceptibility mapping findings of pantothenate kinase-associated neurodegeneration. Journal of Clinical Neuroscience, 59, 20-28. https://doi.org/10.1016/j.jocn.2018.10.090
  11. Alvarez-Cordoba, M., Villanueva-Paz, M., Villalón-García, I., Povea-Cabello, S., Suárez-Rivero, J. M., Talaverón-Rey, M., Abril-Jaramillo, J., Vintimilla-Tosi, A. B., & Sánchez-Alcázar, J. A. (2019). Precision medicine in pantothenate kinase-associated neurodegeneration. Neural Regeneration Research, 14(7), 1177-1185. https://doi.org/10.4103/1673-5374.251203
  12. Klopstock, T., Tricta, F., Neumayr, L., Karin, I., Zorzi, G., Fradette, C., Kmieć, T., Büchner, B., Steele, H. E., Horvath, R., Chinnery, P. F., Basu, A., Küpper, C., Neuhofer, C., Kálmán, B., Dušek, P., Yapici, Z., Wilson, I., Zhao, F., Zibordi, F., … Vichinsky, E. (2019). Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration: a randomised, double-blind, controlled trial and an open-label extension study. The Lancet. Neurology, 18(7), 631-642. https://doi.org/10.1016/S1474-4422(19)30142-5
  13. Sharma, L. K., Subramanian, C., Yun, M. K., Frank, M. W., White, S. W., Rock, C. O., Lee, R. E., & Jackowski, S. (2018). A therapeutic approach to pantothenate kinase associated neurodegeneration. Nature Communications, 9(1), Article 4399. https://doi.org/10.1038/s41467-018-06703-2
  14. Kumar, R., Taneja, N., & Gandhi, R. (2018). Anesthetic management of a case of neurodegeneration brain iron accumulation (Hallervorden-Spatz disease). Journal of Anaesthesiology, Clinical Pharmacology, 34(2), 278-279. https://doi.org/10.4103/joacp.JOACP_103_16
  15. De Vloo, P., Lee, D. J., Dallapiazza, R. F., Rohani, M., Fasano, A., Munhoz, R. P., Ibrahim, G. M., Hodaie, M., Lozano, A. M., & Kalia, S. K. (2019). Deep brain stimulation for pantothenate kinase-associated neurodegeneration: A meta-analysis. Movement Disorders, 34(2), 264-273. https://doi.org/10.1002/mds.27563
  16. Tanrıkulu, B., Özen, A., Günal, D. I., Türkdoğan, D., Bayraklı, F., Bayri, Y., Dağçınar, A., & Şeker, A. (2015). Deep brain stimulation as treatment for dystonic storm in pantothenate kinase-associated neurodegeneration syndrome: case report of a patient with homozygous C.628 2 T > G mutation of the PANK2 gene. Acta Neurochirurgica, 157(9), 1513-1517. https://doi.org/10.1007/s00701-015-2514-5
  17. Stetsenko, T. I., & Konoplyanko, T. V. (2013). Khvoroba Hallevordena-Shpattsa. Suchasnyi pohliad na etiolohiiu, patohenez i kliniku u ditei ta doroslykh [Hallervorden-Spatz disease. Modern view on etiology, pathogenesis and clinic in children and adults]. Sovremennaya pediatriya, (3), 147-150. [in Ukrainian].

Downloads

Published

2021-09-01

How to Cite

1.
Antypkin YH, Kyrylova LH, Miroshnykov OO, Yuzva OO, Silaieva LY, Berehela OV, Myroniak LA. Pantothenate kinase-associated neurodegeneration (Hallerworden–Spatze disease): clinical aspects, diagnosis, treatment (literature review and own data). Zaporozhye Medical Journal [Internet]. 2021Sep.1 [cited 2026May9];23(5):715-22. Available from: https://zmj.zsmu.edu.ua/article/view/222677

Issue

Vol. 23 No. 5 (2021)

Section

Review

License

Authors who publish with this journal agree to the following terms:

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.  Лицензия Creative Commons